Development of a high throughput human stool specimen processing method for a molecular Helicobacter pylori clarithromycin resistance assay

Autoři: Natalie Clines aff001;  Erin Beckman aff001
Působiště autorů: Meridian Bioscience, Inc., Cincinnati, Ohio, United States of America aff001
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article


It has become critical to detect Helicobacter pylori (H. pylori) infection due to the link to gastric cancer with some strains. These strains are also increasing in resistance to antibiotics with clarithromycin leading the way as the first line treatment. Resistance to clarithromycin has been shown to correlate with the A2142G, A2142C, and A2143G mutations on the rrl gene. In the last few decades, non-invasive specimens, such as stool, have been a reliable alternate to gastric biopsy for immunoassay tests. More recently, it has been proven feasible for stool to be used in molecular based tests. Many of the core laboratories in the United States need a high throughput sample preparation to run this test. Here, a high throughput assay is compared to a previously published manual sample prep H. pylori molecular based assay. Using the Magna Pure 96 (Roche), at least 96 stool species and 96 biopsy specimens can be tested in an 8-hour shift of a clinical lab. The high throughput sample prep had a positive percent agreement (PPA) of 87% compared to the manual sample prep using the same testing configuration. The genotype predictions from the high throughput assay matched genotype predictions from the manual sample prep with the same stool sample 92% of the time. A concordance rate of 89% was observed with genotype predictions from the high throughput assay of the same patient stool and biopsy. In stool samples from the high throughput assay, there was 100% concordance between the quantitative polymerase chain reaction (qPCR)-derived genomic prediction and DNA sequencing data. The high throughput workflow can get more patients tested faster in addition to detection of mutations associated with clarithromycin resistance.

Klíčová slova:

Antibiotic resistance – Antibiotics – Biopsy – Helicobacter pylori – Helicobacter pylori infection – High throughput sequencing – Lysis (medicine) – Specimen preparation and treatment


1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. World gastroenterology organization global guideline: Helicobacter pylori in developing countries. J Gastrointestin Liver Dis. 2011; 20(3):299–304. 21961099

2. Infection and Helicobacter pylori. IARC Monogr Eval Carcinog Rosks Hum 1994; 61:177–240.

3. De Vries AC, Kuipers EJ. Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007; 26(2):25–35.

4. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol. 2007; 21(2):299–313. doi: 10.1016/j.bpg.2006.11.002 17382278

5. Luo JC. Noninvasive diagnostic methods for Helicobacter pylori infection. J of Chinese Med Assoc. 2015; 78:83–84.

6. Fallone CA, Chiba N, vanZanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016; 151 (10): 51–69.

7. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017; 112: 212–239. doi: 10.1038/ajg.2016.563 28071659

8. Mitui M, Patel A, Leos NK, Doern CD, Park JY. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. J Ped Gastroenterol and Nut 2014; 59(1):6–9.]

9. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy of triple theory in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14(12):1639–43. doi: 10.1046/j.1365-2036.2000.00870.x 11121913

10. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Et al. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013; 4(3):43–46. doi: 10.4291/wjgp.v4.i3.43 23946886

11. Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, et al. A novel stool PCR test for helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate. J Clin Microbiol. 2017; 55 (8): 2400–2405. doi: 10.1128/JCM.00506-17 28515219

12. Abdollahi H, Savari M, Javad Zahedi M, Darvish Moghadam S, Hayatbakhsh A. Detection of the A2142C, A2142G, A2143G Mutations in 23S rRNA gene conferring resistance to clarithromycin among Helicobacter pylori isolates in Kerman, Iran. Iran J Med Sci. 2011; 36(2): 104–110. 23359224

13. Ribeiro ML, Vitiello L, Miranda MCB, Benvengo YHB, Godoy APO, Mendonca S, et al. Mutations in the 23S rRNA gene are associated with clarithromycin resistance in Helicobacter pylori isolates in Brazil. Ann Clin Microbiol Antimicrob. 2003; 2: 11. doi: 10.1186/1476-0711-2-11 14633281

14. Wang G, Rahman MS, Humayun MZ, and Taylor DE. Multiplex sequence analysis demonstrates the competitive growth advantage of A-to)G mutants of clarithromycin resistant Helicobacter pylori. Antimicrob Agents Chemother. 1999; 43(3): 683–685. 10049289

15. Cao Q, Didelot X, Wu Z, Li Z, He L, Li Y, et al. Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis. Gut. 2015; 64(4):554–61. doi: 10.1136/gutjnl-2014-307345 25007814

Článek vyšel v časopise


2019 Číslo 12
Nejčtenější tento týden